RxDoctor Payments Data

Michael Foster, MD

Interventional Cardiology · Columbia, SCNPI 1780625269

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Shockwave Medical, Inc at 37.5% of the total. Reporting peaked in 2023 at $9,327 and has fallen 60.6% since, to $3,679 in 2025.

$22,807in general payments, 2019–2025

Across 238 payments — averaging $95.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$9K
  • Medtronic$7K
  • Boston Scientific$3K
  • Abiomed$752
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$497
  • Novartis$433
  • plus $2K from 27 others
$51,247in research payments, 2019–2025

Across 10 payments — averaging $5124.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$32K
  • Abbott$19K

What the payments were for

  • Speaking & faculty fees$6,60029%
  • Travel & lodging$7,54133%
  • Food & beverage$8,66638%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,807 in reported general payments places this provider in the 75th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$356,579
Medicare patients
886
Services billed
4,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$253,257
EntrestoSacubitril/Valsartan138$165,296
Repatha SureclickEvolocumab93$99,512
JardianceEmpagliflozin106$95,894
XareltoRivaroxaban87$78,407
FarxigaDapagliflozin Propanediol63$64,593
Praluent PenAlirocumab26$23,933
MultaqDronedarone Hcl16$17,987
OzempicSemaglutide18$17,011
BrilintaTicagrelor24$12,187
EdarbyclorAzilsartan Med/Chlorthalidone25$9,590
VascepaIcosapent Ethyl16$8,530
Metoprolol Succinate438$6,492
Rosuvastatin Calcium345$5,789
Atorvastatin Calcium322$4,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$83$253,257239 claims
NovartisEntresto$433$165,296138 claims
Johnson & JohnsonXarelto$203$78,40787 claims
AstraZenecaFarxiga, Brilinta$306$76,78087 claims
Sanofi-aventis U.S. LLCMultaq$15$17,98716 claims
Novo NordiskOzempic$19$17,01118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →